FDA Orphan Drug Designation for Bexmarilimab
Faron Pharmaceuticals Ltd. (“Faron” or “the Company”) Inside Information: Faron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myeloid Leukemia · ODD further strengthens bexmarilimab program by offering clinical development and commercialization benefits · Expected completion of dose escalation, readout of enrichment cohorts, and Phase II initiation in Q4 2023 Company Announcement, August 29, 2023 Inside Information TURKU, Finland / BOSTON, Massachusetts – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-